The newly reconstituted CDC Advisory Committee on Immunization Practices will meet this week. Packed with antivaxxers, the ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

Companies such as Novavax and Moderna have faced regulatory delays and are ... Minter added that ACIP and FDA’s viewpoints ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

The FDA’s approval was based on a study of 11,400 people ages 12 and older that compared the new low-dose vaccine with Moderna’s existing vaccine. It found that the new vaccine was safe and was at ...

After years of strategic pivots and battling the bureaucracy, Novavax (NASDAQ:NVAX) has finally secured full FDA approval of their COVID-19 vaccine, NUVAXOVID. Not only does the BLA approval ...